Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

from a patient's tumor. Specifid is currently under clinical investigation in a Phase 3 registration trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to fund operations through the primary endpoint analysis of its Phase 3 clinical registration trial progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; whether Favrille's lenders require a letter of credit equal to its outstanding loan balances and the related use of cash; Favrille's ability to obtain additional financing to support its operations; changes in timelines for the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of Specifid and whether it will receive expedited review as a result of the Fast Track designa
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... IL (PRWEB) November 26, 2014 In ... is giving customers a bevy of last-minute Thanksgiving savings. ... codes and offers across all product lines this holiday ... , Thanksgiving, Black Friday, and Cyber Monday are ... its' own thanks to both loyal customers and those ...
(Date:11/26/2014)... Baltimore, MD (PRWEB) November 26, 2014 ... invite the Baltimore and Washington D.C. science community ... research. , The event, sponsored by the Protein Society, ... in UMBC’s University Center, Room 312. Through discussion, ... functional and structural importance of proteins, their role in ...
(Date:11/26/2014)... 25, 2014 SonaCare Medical, a ... (HIFU) devices, recently participated in the American Urology ... 360° .” Key opinion leaders in urology presented ... to small renal masses while attendees had the ... technologies in hands-on labs. Attendees at the Los ...
(Date:11/26/2014)... Global biostimulants market is expected to reach $2,524.02 ... of 12.5%. In order to cater to the ... impacts, farmers are looking to adopt natural compounds ... effectively & efficiently. Biostimulants are consequently seen as ... investments. , Leading companies in the biostimulants market ...
Breaking Biology Technology:DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4
... 2011 The New York Stem Cell Summit is releasing ... the press and the general public understand more accurately the ... the United States today. Approximately 1 million patients ... mid-1980s in the United States. Harvesting stem ...
... 2011 Renmatix , the leading producer of cellulosic sugars, ... fuels company Amyris , has joined the Renmatix Board of ... Year" by the Philadelphia Business Journal , will fill the ... Melo comes to the Renmatix Board of Directors with rare ...
... Sept. 13Researchers at Vanderbilt University have developed a new technique ... biological tissue at multiple points simultaneously, a method that could ... grow and change shape. UV lasers are a ... make incisions by vaporizing one point at a time in ...
Cached Biology Technology:New York Stem Cell Summit Issues Adult Stem Cell Fact Sheet 2Amyris Chief Joins Renmatix BoD, New CFO Added to Company 2
(Date:11/4/2014)... nature, the right amount of death at the right ... according to new research that could help in understanding ... stocks. , In a paper in the journal ... researcher and European colleagues conclude that the kind of ... loss of individuals, or mortality, depends on the size ...
(Date:11/4/2014)... A majority of Madagascar,s 101 species of lemurs are ... for the rainforests they call home. A new study ... can have on rainforest tree populations, which raises concerns ... the region,s rich biodiversity. , A large proportion of ... Lemurs in turn disperse the seeds of their ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... incredibly temperature sensitive and can perceive changes of as little ... 8th issue of the journal Cell , a Cell ... rise, but also coordinate an appropriate response -- activating hundreds ... about the way that their DNA is packaged. The ...
... gardening world it may have always been considered a fact, ... watering your garden in the midday sun can lead to ... in New Phytologist , provides an answer that not ... for forest fires and human sunburn. "The problem ...
... project E! 3184 Odysseus has developed systems to ... tumours or other pathologies, from MRI or CT-scans. The ... location, for consultation in real time just before surgery. ... with the best possible diagnostic support, before real surgery ...
Cached Biology News:How plants 'feel' the temperature rise 2Can a drop of water cause sunburn or fire? 2A virtual liver, a better chance of life 2A virtual liver, a better chance of life 3